Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia 1

Interventions

fludarabine 7Tacrolimus 6Cyclophosphamide 6Whole-Body Irradiation 5Mycophenolic Acid 5Busulfan 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Imatinib Mesylate 4Cytarabine 4Sirolimus 3Melphalan 3thymoglobulin 2asciminib 2Thiotepa 2Patient Reported Outcome Measures 2Mesna 2Bone Marrow Transplantation 2Antilymphocyte Serum 2venetoclax 1ponatinib 1pegfilgrastim 1nilotinib 1nicotinamide-beta-riboside 1methanesulfonic acid 1lonafarnib 1lestaurtinib 1glasdegib 1flumatinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid × glasdegib × Clear all
NCT01841333 2022-01-25

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

University of Colorado, Denver

Phase 2 Completed
31 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡